Key takeaways
Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) and Complera (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) are both combination treatments for HIV, but they have some key differences. Genvoya includes four medications: two NRTIs (emtricitabine and tenofovir alafenamide), an INSTI (elvitegravir), and a booster (cobicistat). Complera, on the other hand, contains three medications: two NRTIs (emtricitabine and tenofovir disoproxil fumarate) and an NNRTI (rilpivirine). Both medications are not available in generic forms. Genvoya is taken once daily with food, while Complera also requires food but specifies a meal of at least 400 calories and is not a first-choice treatment due to newer options with fewer side effects. Complera can be used during pregnancy, whereas Genvoya cannot. Both medications have similar side effects like nausea and headaches, but Complera is more associated with mood changes and depression. Additionally, Genvoya has a booster to enhance the effectiveness of its components, which Complera lacks.
